We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ginkgo Bioworks Holdings, Inc. (DNA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) closed the most recent trading day at $2.78, moving +0.72% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.74%. Meanwhile, the Dow gained 0.01%, and the Nasdaq, a tech-heavy index, added 0.15%.
Coming into today, shares of the company had lost 4.5% in the past month. In that same time, the Medical sector gained 4.57%, while the S&P 500 gained 4.58%.
Investors will be hoping for strength from Ginkgo Bioworks Holdings, Inc. as it approaches its next earnings release. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$0.16 per share. This would mark a year-over-year decline of 128.57%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $54.28 million, down 30.07% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.79 per share and revenue of $418.55 million, which would represent changes of -426.67% and +33.37%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc.Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 26.03% lower. Ginkgo Bioworks Holdings, Inc. currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ginkgo Bioworks Holdings, Inc. (DNA) Gains As Market Dips: What You Should Know
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) closed the most recent trading day at $2.78, moving +0.72% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.74%. Meanwhile, the Dow gained 0.01%, and the Nasdaq, a tech-heavy index, added 0.15%.
Coming into today, shares of the company had lost 4.5% in the past month. In that same time, the Medical sector gained 4.57%, while the S&P 500 gained 4.58%.
Investors will be hoping for strength from Ginkgo Bioworks Holdings, Inc. as it approaches its next earnings release. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$0.16 per share. This would mark a year-over-year decline of 128.57%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $54.28 million, down 30.07% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.79 per share and revenue of $418.55 million, which would represent changes of -426.67% and +33.37%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc.Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 26.03% lower. Ginkgo Bioworks Holdings, Inc. currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.